Related Topics News -

     
 Title only   |   Print    Next page > 
     
聯邦制藥收取諾和就UBT251里程碑付款 涉900萬美元

2026-09-25T  
《大行》瑞銀:中國製藥股上半年業績好壞參半 首選先聲藥業

2026-09-09T  
諾和諾德:後期試驗顯示司美格魯肽可改善兒童肥胖率

2026-09-08T  
聯邦制藥UBT251注射液完成中國2型糖尿病III期臨床首例給藥

2026-09-08T  
《大行》瑞銀降聯邦制藥目標價至12.8元 上半年純利符預期評級「買入」

2026-09-07T  
聯邦制藥UBT251注射液完成中國超重/肥胖III期臨床首例給藥

2026-09-07T  
《大行》中金降聯邦制藥目標價至12元 上半年經調整利潤符預期

2026-09-02T  
《業績》聯邦制藥中期純利3.48億人民幣 倒退81.6%

2026-09-01T  
《盈警》聯邦制藥料中期淨溢利降82%至3.4億人幣

2026-08-20T  
聯邦制藥UBT48128片獲美FDA臨床試驗批准

2026-08-11T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.